Clinical trial
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic…
NCT00451997 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00451997 |
|---|---|
| Title | Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes |
| Official title | Phase II Trial of Gleevec and Low-Dose Ara-C for Elderly Patients With C-Kit Positive Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Gleevec, Ara-C |
| Enrollment | 10 |
| Start date | Mar 1, 2004 |
| Primary completion | Aug 1, 2005 |
| Completion | Apr 1, 2007 |
| First posted | Mar 26, 2007 |
| Last update posted | Aug 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: